Use of Recombinant Activated Factor VII in Primary Postpartum Hemorrhage
Authors:
- Zarko AlfirevicZAZarko Alfirevic
- Diana ElbourneDEDiana Elbourne
- Sue PavordSPSue Pavord
- Antoinette BolteABAntoinette Bolte
- Herman Van GeijnHGHerman Van Geijn
- Frederic MercierFMFrederic Mercier
- Jouni AhonenJAJouni Ahonen
- Katarina BremmeKBKatarina Bremme
- Birgit BødkerBBBirgit Bødker
- Ebba Margrét MagnúsdóttirEMEbba Margrét Magnúsdóttir
- Kjell SalvesenKSKjell Salvesen
- Walter PrendivilleWPWalter Prendiville
- 1 December 2007
- journal article
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 110 (6) , 1270-1278
Abstract
To collect data from nine European countries for cases of obstetric hemorrhage between 2000 and 2004 in which recombinant activated factor VII (rFVIIa) was used. The cases were identified through national surveys. Standardized case report forms included sociodemographic details, past medical and obstetric history, and details of the progress and management of labor in which the postpartum hemorrhage occurred. Clinicians were asked to describe subjectively the effect of rFVIIa administration using two mutually exclusive categories: 1) bleeding reduced or 2) bleeding unchanged or worse. A total of 113 forms were returned (88%) with 97 (86%) classified as treatment, and 16 (14%) as "secondary prophylaxis." Clinicians noted improvements after a single dose for 80% of women in the treatment group, and for 75% in the secondary "prophylaxis" group. However, rFVIIa failed in 15 cases (13.8%). Few serious adverse events were noted related to rFVIIa administration; there were four cases of thromboembolism, one myocardial infarction, and one skin rash. Clinical reports and hematologic data suggest improvement for more than 80% of women after rFVIIa administration and few adverse effects. II.Keywords
This publication has 13 references indexed in Scilit:
- Recombinant factor VIIa in the management of postpartum bleeds: an audit of clinical useActa Obstetricia et Gynecologica Scandinavica, 2006
- WHO analysis of causes of maternal death: a systematic reviewThe Lancet, 2006
- Recombinant factor VIIa for life-threatening post-partum haemorrhage † †This article is accompanied by the Editorial.British Journal of Anaesthesia, 2005
- A worldwide review of the uses of the uterine compression suture techniques as alternative to hysterectomy in the management of severe post-partum haemorrhageJournal of Obstetrics and Gynaecology, 2005
- Misoprostol to treat postpartum haemorrhage: a systematic reviewBJOG: An International Journal of Obstetrics & Gynaecology, 2005
- Incidence of severe pre‐eclampsia, postpartum haemorrhage and sepsis as a surrogate marker for severe maternal morbidity in a European population‐based study: the MOMS‐B surveyBJOG: An International Journal of Obstetrics & Gynaecology, 2004
- Hypogastric Arterial Selective and Superselective Embolization for Severe Postpartum Hemorrhage: A Retrospective Review of 36 CasesCardioVascular and Interventional Radiology, 2004
- Major postpartum hemorrhage: survey of maternity units in the United KingdomActa Obstetricia et Gynecologica Scandinavica, 2002
- NovoSeven® as a universal haemostatic agentBlood Coagulation & Fibrinolysis, 2000
- Evidence for tissue factor-dependent activation of the classic extrinsic coagulation mechanism in blood obtained from bleeding time woundsBlood, 1988